** Shares of Lucid Diagnostics LUCD.O down ~25% to $1.24 in extended trading on equity raise plans
** New York-based commercial-stage subsidiary of PAVmed Inc PAVM.O announces stock offering without disclosing deal size
** With ~90.75 mln shares outstanding, co has about $150 mln market cap
** Stock on Weds finished up 1.9% at $1.65. Shares ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for proposed offering
** Lucid says it's focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。